BE555319A - - Google Patents

Info

Publication number
BE555319A
BE555319A BE555319DA BE555319A BE 555319 A BE555319 A BE 555319A BE 555319D A BE555319D A BE 555319DA BE 555319 A BE555319 A BE 555319A
Authority
BE
Belgium
Application number
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Publication date
Publication of BE555319A publication Critical patent/BE555319A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Otolaryngology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BE555319D 1956-03-21 BE555319A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US572788A US2868691A (en) 1956-03-21 1956-03-21 Self-propelling compositions for inhalation therapy containing a salt of isoproterenol or epinephrine

Publications (1)

Publication Number Publication Date
BE555319A true BE555319A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1900-01-01

Family

ID=24289356

Family Applications (1)

Application Number Title Priority Date Filing Date
BE555319D BE555319A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 1956-03-21

Country Status (3)

Country Link
US (1) US2868691A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE555319A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
GB (1) GB830426A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (135)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051621A (en) * 1959-10-22 1962-08-28 Grove Lab Inc Gel composition, pressurized container with same, and method of preparation
US3050443A (en) * 1960-02-16 1962-08-21 James F Schuyler Headache remedy containing ammonia
US3039928A (en) * 1960-03-17 1962-06-19 Abbott Lab Stable aqueous isoproteronol compositions
NL262354A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1960-03-17
US3088874A (en) * 1960-05-23 1963-05-07 Union Carbide Corp Powder aerosol
US3282781A (en) * 1960-11-25 1966-11-01 Merck & Co Inc Inhalant compositions
BE632504A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1962-05-24
US3169095A (en) * 1962-10-30 1965-02-09 Rexall Drug Chemical Self-propelling powder-dispensing compositions
NL302251A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1963-01-28 1965-10-11
US3710782A (en) * 1969-10-01 1973-01-16 Hauser Res And Eng Co Method of treating human skin with a composition for electromedical applications
FI770215A7 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1976-01-30 1977-07-31 Fisons Ltd
AU522792B2 (en) * 1977-07-19 1982-06-24 Fisons Plc Pressure pack formulation
US4352789A (en) * 1980-03-17 1982-10-05 Minnesota Mining And Manufacturing Company Aerosol compositions containing finely divided solid materials
US4655231A (en) * 1984-01-09 1987-04-07 Advanced Tobacco Products, Inc. Snuff and preparation thereof
US4576949A (en) * 1984-05-07 1986-03-18 The Upjohn Company Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
EP0213108A3 (de) * 1985-06-26 1987-07-15 Kurt Dr. Burghart Pharmazeutische Zubereitung mit einem Antihypotonikum als wirksames Mittel
JPH0645538B2 (ja) * 1987-09-30 1994-06-15 日本化薬株式会社 ニトログリセリンスプレー剤
FR2625677A1 (fr) * 1988-01-07 1989-07-13 Cosnier Alain Composition medicamenteuse destinee a etre administree sous forme d'aerosol
DE68915203T2 (de) * 1988-03-22 1994-09-22 Fisons Plc, Ipswich, Suffolk Pharmazeutische Mischungen.
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
US5776434A (en) * 1988-12-06 1998-07-07 Riker Laboratories, Inc. Medicinal aerosol formulations
US5439670A (en) * 1989-11-28 1995-08-08 Riker Laboratories, Inc. Medicinal aerosol formulations
DE4003270A1 (de) * 1990-02-03 1991-08-08 Boehringer Ingelheim Kg Neue treibgase und ihre verwendung in arzneimittelzubereitungen
US5118494A (en) * 1990-03-23 1992-06-02 Minnesota Mining And Manufacturing Company Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
US5175152A (en) * 1990-09-28 1992-12-29 Singh Nikhilesh N Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
MX9203481A (es) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg Formulaciones.
US5919435A (en) 1990-11-09 1999-07-06 Glaxo Group Limited Aerosol formulation containing a particulate medicament
US5785952A (en) * 1990-11-09 1998-07-28 Glaxo Group Limited Aerosol medicament formulation having a surface coating of surfactant
ES2158908T3 (es) 1991-06-10 2001-09-16 Schering Corp Formulaciones en aerosol sin clorofluorocarbonos.
US5234933A (en) * 1991-10-31 1993-08-10 Board Of Governors Of Wayne State University And Vanderbilt University Cyclic hydroxamic acids
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5916540A (en) * 1994-10-24 1999-06-29 Glaxo Group Limited Aerosol formulations containing P134A and/or P227 and particulate medicament
EP0616525B1 (en) * 1991-12-12 1995-09-27 Glaxo Group Limited Pharmaceutical aerosol formulation
IL104068A (en) * 1991-12-12 1998-10-30 Glaxo Group Ltd Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
US5653962A (en) * 1991-12-12 1997-08-05 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
JP3026841B2 (ja) * 1991-12-12 2000-03-27 グラクソ、グループ、リミテッド 医 薬
US5744123A (en) * 1991-12-12 1998-04-28 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicaments
US5658549A (en) * 1991-12-12 1997-08-19 Glaxo Group Limited Aerosol formulations containing propellant 134a and fluticasone propionate
US7101534B1 (en) 1991-12-18 2006-09-05 3M Innovative Properties Company Suspension aerosol formulations
US7105152B1 (en) 1991-12-18 2006-09-12 3M Innovative Properties Company Suspension aerosol formulations
JP3908269B2 (ja) * 1991-12-18 2007-04-25 スリーエム カンパニー 懸濁エアゾール製剤
AU6048694A (en) * 1992-12-09 1994-07-04 Paul D. Jager Stabilized medicinal aerosol solution formulations
DE69408373T2 (de) * 1993-06-01 1998-07-16 Ono Pharmaceutical Co Pentansäurederivate
EP0640609A1 (en) * 1993-08-24 1995-03-01 Ono Pharmaceutical Co., Ltd. Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
DE69409471T2 (de) * 1993-12-03 1998-08-27 Ono Pharmaceutical Co Amidinophenolderivate mit Phospholipase A2 inhibitorischer Wirkung
DK0735884T3 (da) * 1993-12-20 2000-10-09 Minnesota Mining & Mfg Flunisolid-aerosolformuleringer
KR100226619B1 (ko) 1994-09-20 1999-10-15 우에노 토시오 아미디노페놀 유도체
US5840213A (en) * 1995-04-28 1998-11-24 Great Lakes Chemical Corporation Uses of heptafluoropropane
US5679287A (en) * 1995-04-28 1997-10-21 Great Lakes Chemical Corporation Uses of heptafluoropropane
KR980009238A (ko) 1995-07-28 1998-04-30 우에노 도시오 설포닐아미노산 유도체
ATE226936T1 (de) * 1995-08-08 2002-11-15 Ono Pharmaceutical Co Hydroxamsäurederivate verwendbar zur hemmung von gelatinase
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
US5861268A (en) * 1996-05-23 1999-01-19 Biomide Investment Limited Partnership Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
US6054488A (en) * 1996-06-11 2000-04-25 3M Innovative Properties Company Medicinal aerosol formulations of formoterol
GB9616237D0 (en) * 1996-08-01 1996-09-11 Norton Healthcare Ltd Aerosol formulations
AU718967B2 (en) 1997-02-05 2000-05-04 Jagotec Ag Medical aerosol formulations
US6129905A (en) * 1997-04-21 2000-10-10 Aeropharm Technology, Inc. Aerosol formulations containing a sugar as a dispersant
US5891419A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe flunisolide aerosol formulations for oral inhalation
US5891420A (en) * 1997-04-21 1999-04-06 Aeropharm Technology Limited Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
US7153866B1 (en) * 1997-05-27 2006-12-26 The United States Of America As Represented By The Department Of Health And Human Services Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
US20010031244A1 (en) * 1997-06-13 2001-10-18 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol composition
JPH11187882A (ja) 1997-12-26 1999-07-13 Ono Pharmaceut Co Ltd 新規なポリペプチド、その製造方法、そのポリペプチドをコードするｃＤＮＡ、そのｃＤＮＡからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
EP1100465B1 (de) 1998-07-24 2004-11-24 Jago Research Ag Medizinische aerosolformulierungen
DE59904648D1 (de) 1998-08-04 2003-04-24 Jago Res Ag Muttenz Medizinische aerosolformulierungen
US6136294C1 (en) * 1998-09-22 2002-09-24 Aeropharm Technology Inc Amino acid stabilized medical aerosol formulation
US6458338B1 (en) 1998-09-22 2002-10-01 Aeropharm Technology Incorporated Amino acid stabilized medicinal aerosol formulations
DZ2947A1 (fr) * 1998-11-25 2004-03-15 Chiesi Farma Spa Inhalateur à compteur de dose sous pression.
US6315985B1 (en) * 1999-06-18 2001-11-13 3M Innovative Properties Company C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US7608637B2 (en) 2001-07-23 2009-10-27 Ono Pharmaceutical Co., Ltd. Pharmaceutical composition for treatment of diseases associated with decrease in bone mass comprising EP4 agonist as the active ingredient
EP1477175B1 (en) 2002-02-19 2011-04-27 Ono Pharmaceutical Co., Ltd. Fused pyridazine derivative compounds and drugs containing the compounds as the active ingredient
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
US20050186141A1 (en) * 2002-06-25 2005-08-25 Acrux Dds Pty Ltd. Transdermal aerosol compositions
JP5160018B2 (ja) * 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
US20050181032A1 (en) * 2002-06-25 2005-08-18 Acrux Dds Pty Ltd. Metastable pharmaceutical compositions
AU2003248245A1 (en) 2002-06-26 2004-01-19 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
AU2003281200A1 (en) 2002-07-03 2004-01-23 Tasuku Honjo Immunopotentiating compositions
US7820682B2 (en) 2002-10-03 2010-10-26 Ono Pharmaceutical Co., Ltd. LPA receptor antagonist
JPWO2004032964A1 (ja) * 2002-10-10 2006-02-09 国立大学法人京都大学 アレルギー性疾患治療剤
TW200413000A (en) 2002-10-10 2004-08-01 Ono Pharmaceutical Co Intrinsic repair factor producing accelerator
WO2004072286A1 (ja) 2003-01-23 2004-08-26 Ono Pharmaceutical Co., Ltd. ヒトｐｄ−１に対し特異性を有する物質
TW201018661A (en) 2003-03-14 2010-05-16 Ono Pharmaceutical Co Heterocyclic rinf having nitrogen atom derivatives and medicament containing the derivatives as active ingredient
EP1619193A4 (en) 2003-04-18 2010-08-11 Ono Pharmaceutical Co SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
CA2526222A1 (en) * 2003-05-16 2004-12-02 Arriva Pharmaceuticals, Inc. Treatment of respiratory disease associated with matrix metalloprotease inhibitors
WO2006031210A1 (en) * 2003-05-29 2006-03-23 Board Of Regents, The University Of Texas Systems Jabi as a prognostic marker and a therapeutic target for human cancer
EP2422814A1 (en) 2003-07-25 2012-02-29 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
MXPA06002310A (es) 2003-08-29 2006-05-25 Ono Pharmaceutical Co Compuesto capaz de enlazarse al receptor s1p y uso farmaceutico del mismo.
ES2425746T3 (es) 2003-09-01 2013-10-17 Ono Pharmaceutical Co., Ltd. Compuesto cíclico condensado y uso del mismo
WO2005025506A2 (en) * 2003-09-10 2005-03-24 Map Pharmaceuticals, Inc. Aerosol formulations for delivery of dihydroergotamine to the systemic circulation via pulmonary inhalation
KR20060106823A (ko) * 2003-10-20 2006-10-12 쉐링 코포레이션 약제학적 에어로졸 조성물
JP4792974B2 (ja) 2003-12-25 2011-10-12 小野薬品工業株式会社 アゼチジン環化合物およびその医薬
WO2006004646A1 (en) * 2004-06-28 2006-01-12 Nektar Therapeutics Aerosol formulation comprising nicotine salt
JP5272310B2 (ja) 2004-10-21 2013-08-28 小野薬品工業株式会社 免疫抑制受容体の用途
AU2005309951B2 (en) * 2004-11-24 2011-07-07 Alcon, Inc. Method of delivering nasal spray
US8563581B2 (en) 2005-02-02 2013-10-22 Mitos Pharmaceuticals, Inc. Nitroxides for use in treating predisposed or at risk patients
US8524734B2 (en) * 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
JP5279487B2 (ja) 2005-05-18 2013-09-04 エムペックス・ファーマシューティカルズ・インコーポレーテッド エアロゾル化フルオロキノロンおよびその使用
JP5756250B2 (ja) 2005-06-17 2015-07-29 ウィスコンシン アラムニ リサーチ ファンデーション 癌の化学療法および放射線療法の際に細胞を保護するための局所的血管収縮剤および方法
DK1942108T3 (da) 2005-10-28 2013-12-09 Ono Pharmaceutical Co Forbindelse indeholdende basisk gruppe samt anvendelse deraf
WO2007069565A1 (ja) 2005-12-12 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
WO2007069671A1 (ja) 2005-12-15 2007-06-21 Ono Pharmaceutical Co., Ltd. 二環式複素環化合物
US20070286814A1 (en) * 2006-06-12 2007-12-13 Medispray Laboratories Pvt. Ltd. Stable aerosol pharmaceutical formulations
WO2008097664A1 (en) * 2007-02-11 2008-08-14 Map Pharmaceuticals, Inc. Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
TW200902019A (en) 2007-04-26 2009-01-16 Ono Pharmaceutical Co Dicyclic heterocyclic compound
DE102008007198A1 (de) 2008-02-01 2009-08-13 Infectopharm Arzneimittel Und Consilium Gmbh Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
SI2346509T1 (sl) 2008-10-07 2020-08-31 Horizon Orphan Llc Inhalacija levofloksacina za zmanjšanje vnetja pljuč
EP2344129B1 (en) 2008-10-07 2018-02-21 Horizon Orphan LLC Aerosol fluoroquinolone formulations for improved pharmacokinetics
TWI469965B (zh) 2008-12-22 2015-01-21 Ono Pharmaceutical Co 乙炔基吲哚化合物
ES2511065T3 (es) 2009-06-17 2014-10-22 Ono Pharmaceutical Co., Ltd. Nuevo compuesto imidazopiridina
WO2010151804A1 (en) * 2009-06-26 2010-12-29 Map Pharmaceuticals, Inc. Administration of dihydroergotamine mesylate particles using a metered dose inhaler
NZ598484A (en) 2009-09-04 2014-02-28 Mpex Pharmaceuticals Inc Use of aerosolized levofloxacin for treating cystic fibrosis
WO2011066537A1 (en) 2009-11-30 2011-06-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
NZ604396A (en) 2010-06-21 2014-05-30 Ono Pharmaceutical Co New crystalline forms of 4,4’-[4-fluoro-7-({ 4-[4-(3-fluoro-2-methylphenyl)butoxy]phenyl} ethynyl)-2-methyl-1h-indole-1,3-diyl]dibutanoic acid, 4,4’-[2-methyl-7-({ 4-[4-(pentafluorophenyl)butoxy]phenyl} ethynyl)-1h-indole-1,3-diyl]dibutanoic acid, and 4,4’-[4-fluoro-2-methyl-7-({ 4-[4-(2,3,4,6-tetrafluorophenyl)butoxy]phenyl} ethynyl)-1h-indole-1,3-diyl]dibutanoic acid tetrafluorophenyl)butoxy]phenyl} ethynyl)-1h-indole-1,3-diyl]dibutanoic acid
WO2012074069A1 (ja) 2010-12-02 2012-06-07 小野薬品工業株式会社 新規化合物及びその医薬用途
AU2012212269B2 (en) 2011-01-31 2016-05-19 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
TW201309698A (zh) 2011-03-18 2013-03-01 Ono Pharmaceutical Co 四氫咔啉衍生物
ES2605388T3 (es) 2012-04-26 2017-03-14 Ono Pharmaceutical Co., Ltd. Compuesto inhibidor de Trk
EP3800183A1 (en) 2013-02-19 2021-04-07 ONO Pharmaceutical Co., Ltd. Urea derivatives as trk-inhibiting compounds
JP6799201B2 (ja) 2013-07-31 2020-12-16 アヴァリン ファーマ インク． エアロゾルチロシンキナーゼ阻害剤の化合物、及びその使用
AU2015204558B2 (en) 2014-01-10 2020-04-30 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
EP3099672A4 (en) 2014-01-31 2017-09-20 ONO Pharmaceutical Co., Ltd. Fused imidazole compounds
JP7209963B2 (ja) 2016-11-30 2023-01-23 住友ファーマ株式会社 Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ
US20210100886A1 (en) 2017-03-30 2021-04-08 Sumitomo Dainippon Pharma Co., Ltd. Wt1 cancer antigen peptides and peptide conjugates comprising the peptides
JPWO2019049891A1 (ja) 2017-09-06 2020-10-15 小野薬品工業株式会社 Ｔｒｋ阻害剤とキナーゼ阻害剤の併用による癌治療方法
TW202015732A (zh) 2018-05-31 2020-05-01 日商小野藥品工業股份有限公司 免疫檢查點阻礙藥的有效性判定用生物標記
TW202446772A (zh) 2018-10-11 2024-12-01 日商小野藥品工業股份有限公司 Ｓｔｉｎｇ促效化合物
BR112022002098A2 (pt) 2019-08-05 2022-04-12 Nat Cancer Ct Biomarcadores para determinar a eficácia de inibidores da via de sinalização imune
TW202134213A (zh) 2019-11-29 2021-09-16 日商小野藥品工業股份有限公司 具有水解磷脂酸受體作動活性之化合物及其醫藥用途
WO2021159077A1 (en) 2020-02-07 2021-08-12 Case Western Reserve University Compositions and methods for attenuating opioid induced cardio and/or respiratory depression
JPWO2021205631A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2020-04-10 2021-10-14
CN115867303A (zh) 2020-05-12 2023-03-28 住友制药株式会社 用于治疗癌症的药物组合物
WO2022240897A1 (en) 2021-05-10 2022-11-17 Sepelo Therapeutics, Llc Pharmaceutical composition comprising delafloxacin for administration into the lung
WO2022251679A1 (en) 2021-05-27 2022-12-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Nitroxide radicals for use as antiviral treatment for coronavirus infection
WO2023028364A1 (en) 2021-08-27 2023-03-02 Sepelo Therapeutics, Llc Targeted compositions and uses therof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2222976A (en) * 1937-11-15 1940-11-26 Sharp & Dohme Inc Nasal drops
US2728495A (en) * 1951-04-19 1955-12-27 Little Inc A Liquid dispensing device and composition therefor

Also Published As

Publication number Publication date
US2868691A (en) 1959-01-13
GB830426A (en) 1960-03-16

Similar Documents

Publication Publication Date Title
AT2876B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT13731B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT1395B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2036B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2340B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT16026B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT12908B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT12945B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT13070B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT13447B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT13673B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IT380973B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2487B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2790B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT13734B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2701B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT13968B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT14030B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT14120B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2710B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT7215B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2896B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT14253B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2872B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT2801B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)